With the creation of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR, U54 AI117804) in 2014, patient advocacy groups (PAGs) were formally incorporated into the unified infrastructure to facilitate research on EGIDs. A notable champion in this process has been the Campaign Urging Research for Eosinophilic Disease (CURED), a PAG that has earned a name in the EGID community for their generosity in helping others. As a partner of CEGIR since its creation, CURED has contributed in many ways, serving on committees, helping to recruit patients, practicing and teaching advocacy, and financially supporting CEGIR in its missions including its Pilot Programs and Career Enhancement (Training) activities. CURED's generosity is not only to help others but to fund CEGIR with $25,000 per year; these funds are used for a number of CEGIR research activities at the discretion of CEGIR. These activities may include partial funding for the Career Enhancement Core (Training Program) and Research Pilot Studies.
The Myasthenia Gravis Rare Disease Network (MGNet) has awarded the 2020 MGNet Scholar Award to Amanda Guidon, MD, a neuromuscular neurologist at the Massachusetts General Hospital and an Assistant Professor of Neurology at Harvard Medical School.
In patients with cavernous angioma (CA), lesions in the brain are caused by imbalances in the gut microbiome, according to a new study in the journal Nature Communications. Data from the Brain Vascular Malformation Consortium (BVMC) helped researchers make this connection, the first of its kind in any human neurovascular disease.
APFED and CEGIR have awarded a 2020 co-funded pilot grant to Paneez Khoury, MD, MHSc, of the @National Institute of Allergy and Infectious Disease’s Human Eosinophil Section, for a promising research study that will provide the first examination of gastric motility in patients with eosinophilic gastritis (EG).
Dr. Khoury’s project will examine if allergy mediated inflammation causes fibrostenotic changes in the stomach tissue to contribute to commonly experienced EG symptoms, such as bloating and early satiety, and if it causes a slower emptying of stomach contents into the small intestine. This important work will influence the selection of drugs that will be studied in future EG clinical trials. Learn more…
Seven patients now have a name for their specific congenital disorder of glycosylation (CDG)—a new type called GALNT2-CDG. Researchers from Frontiers in Congenital Disorders of Glycosylation (FCDGC) describe the new disorder, caused by mutations in the GALNT2 gene, in the journal Brain.
Rare disease patients or their caregivers are invited to complete a 20-minute online survey from home about the ways the novel coronavirus pandemic is impacting people with rare diseases and their families.
What is the genetic cause behind impaired mucociliary clearance of the lungs? Researchers from the Genetic Disorders of Mucociliary Clearance Consortium (GDMCC) contributed to the discovery of a new disease gene, NEK10, that regulates cilia length.